Immunohistochemical Analysis and Mesothelioma Disease (DOC) by anamaulida


									Another interesting study is called, -œUtility of D2-40, a novel
mesothelial marker, in the diagnosis of malignant Mesothelioma-• by
Albert Y Chu, Leslie A Litzky, Theresa L Pasha, Geza Acs and Paul J Zhang
- Department of Pathology and Laboratory Medicine, Hospital of the
University of Pennsylvania, Philadelphia, PA, USA - Modern Pathology
(2005) 18, 105-110. Here is an excerpt: -œAbstract - Although
immunohistochemistry has proven to be valuable in the differentiation of
epithelioid mesothelioma from pulmonary or metastatic adenocarcinoma, no
single antibody has demonstrated absolute sensitivity or specificity in
making this distinction. Using immunohistochemical analysis with D2-40, a
recently available monoclonal antibody that has been used as a lymphatic
endothelial marker, we examined 53 cases of mesothelioma, 28 cases of
reactive pleura, 30 cases of pulmonary adenocarcinoma, 35 cases of renal
cell carcinoma, 26 cases of ovarian serous carcinoma, 16 cases of
invasive breast carcinoma, 11 cases of prostatic adenocarcinoma, and
seven cases of urothelial carcinoma. In addition, immunohistochemistry
using calretinin, cytokeratin 5/6, and WT1 was performed on all cases of
mesothelioma, pulmonary adenocarcinoma, ovarian serous carcinoma, and
renal cell carcinoma. Predominantly, membranous D2-40 immunoreactivity
was present in 51 of 53 (96%) mesotheliomas, 27 of 28 (96%) cases of
reactive pleura, and 17 of 26 (65%) ovarian serous carcinomas; membranous
staining was not seen in any other tumors examined. Compared to other
immunohistochemical markers of mesothelioma, D2-40 was as sensitive as
calretinin and more sensitive than cytokeratin 5/6 and WT1. We conclude
that D2-40 immunoreactivity is sensitive for cells of mesothelial origin,
and may be useful in the differential diagnosis of epithelioid malignant
mesothelioma vs adenocarcinoma.-•        Another interesting study is
called, -œThe Immunohistochemical Diagnostic Panel for Epithelial
Mesothelioma: A Reevaluation After Heat-Induced Epitope Retrieval-• by
Riera, Jose R. M.D.; Astengo-Osuna, Carlos M.D.; Longmate, Jeffrey A.
Ph.D.; Battifora, Hector M.D - American Journal of Surgical Pathology:
December 1997 - Volume 21 - Issue 12 - pp 1409-1419. Here is an excerpt:
-œAbstract - The immunohistochemical diagnosis between epithelial
mesothelioma and adenocarcinoma is currently based on the use of a panel
of antibodies to adenocarcinoma-associated antigens and a few antibodies
to mesothelial-associated antigens. Since the introduction of epitope
retrieval methods, the sensitivity of many antibodies has been enhanced.
Thus, a reevaluation of the mesothelioma/adenocarcinoma diagnostic panel
becomes necessary. We studied 268 paraffin-embedded formalin-fixed tumor
samples that included 57 epithelial mesotheliomas and 211 adenocarcinomas
of various origins, comparing an extensive antibody panel with and
without heat-induced epitope retrieval (HIER). Marked increase in the
sensitivity of several antibodies, with no loss of specificity, was found
when HIER was used. After statistical analysis, the antibodies to the
epithelial glycoproteins carcinoembryonic antigen, BerEp4, and Bg8
emerged as the best discriminators between adenocarcinoma and epithelial
mesothelioma within the entire panel. The mesothelium-associated
antibodies, HBME-1, calretinin, and thrombomodulin were less sensitive
and less specific than the former, although they were found to be useful
on certain cases. Antibodies to cytokeratins and vimentin, although of
minor diagnostic value in this context, may be helpful to evaluate the
quality of antigen preservation. This study confirms the value of
immunohistochemistry to accurately distinguish mesothelioma from
adenocarcinoma when an antibody panel approach is used. The addition of
heat-induced epitope retrieval methods increases the effectiveness of the
procedure and is recommended for most of the antibody panel members.-•

  Another interesting study is called, -œA review of peritoneal
mesothelioma at the Washington Cancer Institute.-• - Surg Oncol Clin N
Am. 2003 Jul;12(3):605-21, xi. By   Sugarbaker PH, Welch LS, Mohamed F,
Glehen O. Here is an excerpt: -œAbstract -    This article reviews a
single institution's experience with 68 patients (21 females, 47 males)
prospectively treated over the last 2 decades with an aggressive local-
regional approach, combining maximal cytoreductive surgery with heated
intraoperative intraperitoneal chemotherapy and early postoperative
intraperitoneal chemotherapy. This multimodality treatment has resulted
in a median survival of 67 months. Female patients had a significantly
better prognosis than males. The other significant predictive factors of
survival were: age, diagnosis by incidental findings, tumor extent,
pathology, and completeness of cytoreduction.-•      We all owe a debt of
gratitude to these fine researchers. If you found any of these excerpts
interesting, please read the studies in their entirety.      Monty
Wrobleski is the author of this article. For more information please
click on the following links       Depuy Hip Recall Attorney      Depuy
Hip Recall Attorney

Related Articles -
Asbestos Exposure, Mesothelioma Cancer, asbestos attorney, lawyer, class
action lawyers, law suit, suite, law firm, law firms, litigation,
Treatment, ,

Email this Article to a Friend!
Receive Articles like this one direct to your email box!Subscribe for
free today!

To top